Theolytics Ltd
Private Limited Company · Oxford
ActiveUnited KingdomIncorporated 2017Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2023-12-31
IXBRL · 226 source facts · 27 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 226 source facts · 27 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 174
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2466_11001290_20231231
- Source archive
- Accounts_Monthly_Data-August2024.zip
Accounts to 2022-10-31
IXBRL · 236 source facts · 25 selected values
Not assessedlegacy record
Accounts to 2022-10-31
IXBRL · 236 source facts · 25 selected values
Not assessed
legacy record
- Reporting period
- 2021-11-01 to 2022-10-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 183
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0015_11001290_20221031
- Source archive
- Accounts_Monthly_Data-May2023.zip
Accounts to 2021-10-31
IXBRL · 236 source facts · 25 selected values
Not assessedlegacy record
Accounts to 2021-10-31
IXBRL · 236 source facts · 25 selected values
Not assessed
legacy record
- Reporting period
- 2020-11-01 to 2021-10-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 183
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0105_11001290_20211031
- Source archive
- Accounts_Monthly_Data-April2022.zip
Accounts to 2020-10-31
IXBRL · 205 source facts · 25 selected values
Not assessedlegacy record
Accounts to 2020-10-31
IXBRL · 205 source facts · 25 selected values
Not assessed
legacy record
- Reporting period
- 2019-11-01 to 2020-10-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 154
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0089_11001290_20201031
- Source archive
- Accounts_Monthly_Data-April2021.zip
Accounts to 2019-10-31
IXBRL · 166 source facts · 20 selected values
Not assessedlegacy record
Accounts to 2019-10-31
IXBRL · 166 source facts · 20 selected values
Not assessed
legacy record
- Reporting period
- 2018-11-01 to 2019-10-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 99
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0076_11001290_20191031
- Source archive
- Accounts_Monthly_Data-March2020.zip
Accounts to 2018-10-31
IXBRL · 125 source facts · 10 selected values
Not assessedlegacy record
Accounts to 2018-10-31
IXBRL · 125 source facts · 10 selected values
Not assessed
legacy record
- Reporting period
- 2017-10-06 to 2018-10-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 52
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0067_11001290_20181031
- Source archive
- Accounts_Monthly_Data-June2019.zip
Registered details
11001290- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2017-10-06
- Jurisdiction
- —
- Registered office
- 4610 KINGSGATE, CASCADE WAY, OXFORD, OXFORDSHIRE, OX4 2SU, ENGLAND
Classification
1 SIC codes23112
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
5 matched grantsA novel phase 1 clinical trial for a next-generation oncolytic therapy targeting treatment of platinum-resistant high-grade serous ovarian cancerLead
Innovate UK · Collaborative R&D · 2024-08-01 – 2026-07-31
£1,991,889
awarded
Engineered Genetic Control Systems for Advanced TherapeuticsActiveBBSRC · Research Grant · 2024-02-14 – 2029-03-30 · with 13 other participants£12,667,418whole project
Engineered Genetic Control Systems for Advanced TherapeuticsActive
BBSRC · Research Grant · 2024-02-14 – 2029-03-30 · with 13 other participants
£12,667,418
whole project
University Of EdinburghleadAstraZenecaBit.BioCell Therapy CatapultHarvard UniversityIBioIC (Industrial Biotech Innov Ctr)Johnson & JohnsonLaverock TherapeuticsLonza AGOxford BioMedica (United Kingdom)PhenomeXSterling Bio Machines LtdSynBioBetaTheolytics Ltd.
Using oncolytic viral therapy to target the tumour microenvironment in chromosomally unstable cancersActiveMRC · Studentship · 2023-09-30 – 2027-09-29 · with 1 other participant£0whole project
Using oncolytic viral therapy to target the tumour microenvironment in chromosomally unstable cancersActive
MRC · Studentship · 2023-09-30 – 2027-09-29 · with 1 other participant
£0
whole project
University Of OxfordleadTheolytics Ltd.
Preclinical validation of a novel oncolytic viral therapy for multiple myeloma targeting readiness for clinical trialsLeadInnovate UK · Collaborative R&D · 2022-05-01 – 2024-04-30 · with 1 other participant£658,140awarded
Preclinical validation of a novel oncolytic viral therapy for multiple myeloma targeting readiness for clinical trialsLead
Innovate UK · Collaborative R&D · 2022-05-01 – 2024-04-30 · with 1 other participant
£658,140
awarded
Theolytics Ltdlead£658,140
A novel platform for arming of candidate oncolytic viruses targeting immunologically cold metastatic ovarian cancerLead
Innovate UK · Study · 2020-11-01 – 2022-04-30
£349,984
awarded
Scaleup signal
OECD growth threshold met
24% employee CAGR